Neuro-Oncology
Reviews


Volume 24 Number 17
15 September 2022


Home > Publications > Neuro-Oncology Reviews > Volume 24, Year 2022 > Number 17, 15 September






Cabezas-Camarero S, Pérez-Alfayate R, Sotelo MJ.
Glioblastoma: an organ-confined disease?
Transl Cancer Res. 2022 Aug, 2022;11(8):2473-2476. doi: 10.21037/tcr-22-1943. PMID: 36093531. Editorial.
Refers to: Chai M, et al., Extracranial metastasis of glioblastoma with genomic analysis: a case report and review of the literature.
Transl Cancer Res. 2022 Aug, 2022;11(8):2917-2925
. doi: 10.21037/tcr-22-955. PMID: 36093544. Case report, Review.




Chai M, Shi Q.
Extracranial metastasis of glioblastoma with genomic analysis: a case report and review of the literature.
Transl Cancer Res. 2022 Aug, 2022;11(8):2917-2925. doi: 10.21037/tcr-22-955. PMID: 36093544. Case report, Review.




Wu JY, Ren AL, Lim M.
Immunometabolism, a new therapeutic development for immunotherapies of high-grade gliomas: a narrative review.
Chin Clin Oncol. 2022 Aug, 2022;11(4):26. doi: 10.21037/cco-22-58. PMID: 36098097. Review.




Zhao MJ, Lu T, Ma C, Wang ZF, Li ZQ.
A narrative review on the management of glioblastoma in China.
Chin Clin Oncol. 2022 Aug, 2022;11(4):29. doi: 10.21037/cco-22-18. PMID: 36098100. Review.




Sankhyan M, Anderson EM, Urquiaga JF, Hockman JT, Aggarwal R, El Tecle NE, Mercier PJ.
Urothelial Carcinoma of the Bladder With Primary Metastasis to the Brain: A Case Report and Literature Review.
Cureus. 2022 Aug 1, 2022;14(8):e27587. doi: 10.7759/cureus.27587. PMID: 36059295. Case report, Review.




Edwards L, Habib A, Zinn PO.
Editorial: Rising stars in neuro-oncology and neurosurgical oncology 2021.
Front Oncol. 2022 Aug 16, 2022;12:940063. doi: 10.3389/fonc.2022.940063. PMID: 36052223. Editorial.




Lu M, Zhou Y, Sun L, Shafi S, Ahmad N, Sun M, Dong J.
The molecular mechanisms of ferroptosis and its role in glioma progression and treatment.
Front Oncol. 2022 Aug 16, 2022;12:917537. doi: 10.3389/fonc.2022.917537. PMID: 36091118. Review.




Wang G, Wang W.
Advanced Cell Therapies for Glioblastoma.
Front Immunol. 2022 Aug 16, 2022;13:904133. doi: 10.3389/fimmu.2022.904133. PMID: 36052072. Review.




Zhang G, Li J, Hui X.
Use of 18F-FDG-PET/CT in differential diagnosis of primary central nervous system lymphoma and high-grade gliomas: A meta-analysis.
Front Neurol. 2022 Aug 17, 2022;13:935459. doi: 10.3389/fneur.2022.935459. PMID: 36061992. Meta-analysis.




Zhuo S, He G, Chen T, Li X, Liang Y, Wu W, Weng L, Feng J, Gao Z, Yang K.
Emerging role of ferroptosis in glioblastoma: Therapeutic opportunities and challenges.
Front Mol Biosci. 2022 Aug 17, 2022;9:974156. doi: 10.3389/fmolb.2022.974156. PMID: 36060242. Review.



*

Onwudiwe K, Burchett AA, Datta M.
Mechanical and metabolic interplay in the brain metastatic microenvironment.
Front Oncol. 2022 Aug 18, 2022;12:932285. doi: 10.3389/fonc.2022.932285. PMID: 36059679. Review.




Shi J, Yang N, Han M, Qiu C.
Emerging roles of ferroptosis in glioma.
Front Oncol. 2022 Aug 22, 2022;12:993316. doi: 10.3389/fonc.2022.993316. PMID: 36072803. Review.




Tian W, Zhang W, Wang Y, Jin R, Wang Y, Guo H, Tang Y, Yao X.
Recent advances of IDH1 mutant inhibitor in cancer therapy.
Front Pharmacol. 2022 Aug 24, 2022;13:982424. doi: 10.3389/fphar.2022.982424. PMID: 36091829. Review.




Akindona FA, Frederico SC, Hancock JC, Gilbert MR.
Exploring the origin of the cancer stem cell niche and its role in anti-angiogenic treatment for glioblastoma.
Front Oncol. 2022 Aug 25, 2022;12:947634. doi: 10.3389/fonc.2022.947634. PMID: 36091174. Review.



*

Ohno M, Kitanaka C, Miyakita Y, Tanaka S, Sonoda Y, Mishima K, Ishikawa E, Takahashi M, Yanagisawa S, Ohashi K, Nagane M, Narita Y.
Metformin with Temozolomide for Newly Diagnosed Glioblastoma: Results of Phase I Study and a Brief Review of Relevant Studies.
Cancers (Basel). 2022 Aug 30, 2022;14(17):4222. doi: 10.3390/cancers14174222. PMID: 36077758. Interventional study, Review.




Pace A, Tanzilli A, Benincasa D.
Prognostication in brain tumors.
Handb Clin Neurol. 2022 Aug 30, 2022;190:149-161. doi: 10.1016/B978-0-323-85029-2.00001-4. PMID: 36055712. Review˰




Sioutas G, Nikova A, Birbilis T.
Risk factors for pediatric glioma.
Folia Med (Plovdiv). 2022 Aug 31, 2022;64(4):566-571. doi: 10.3897/folmed..e64431. PMID: 36045476. Review.




Talloa D, Triarico S, Agresti P, Mastrangelo S, Attinà G, Romano A, Maurizi P, Ruggiero A.
BRAF and MEK Targeted Therapies in Pediatric Central Nervous System Tumors.
Cancers (Basel). 2022 Aug 31, 2022;14(17):4264. doi: 10.3390/cancers14174264. PMID: 36077798. Review.




Jain H, Dhawan P, Rao S, Lalwani N, Shand H.
The impediments of cancer stem cells and an exploration into the nanomedical solutions for glioblastoma.
Anticancer Agents Med Chem. 2022 Sep 1. doi: 10.2174/1871520622666220901101204. PMID: 36056850. Review˰



*

Li S, Dong J, Wang X, Meng X, Jiang C, Cai J.
Dexamethasone and compliance affect TTFields efficacy to glioblastoma patients: a systematic review and meta-analysis.
Chin Neurosurg J. 2022 Sep 3, 2022;8(1):24. doi: 10.1186/s41016-022-00294-0. PMID: 36056409. Review, Meta-analysis.




Yang T, Liu D, Fang S, Ma W, Wang Y.
Cytomegalovirus and Glioblastoma: A Review of the Biological Associations and Therapeutic Strategies.
J Clin Med. 2022 Sep 4, 2022;11(17):5221. doi: 10.3390/jcm11175221. PMID: 36079151. Review.




Davoodvandi A, Nikfar B, Reiter RJ, Asemi Z.
Melatonin and cancer suppression: insights into its effects on DNA methylation.
Cell Mol Biol Lett. 2022 Sep 5, 2022;27(1):73. doi: 10.1186/s11658-022-00375-z. PMID: 36064311. Review.




Low SK, Anjum Z, Mahmoud A, Joshi U, Kouides P.
Isocitrate dehydrogenase mutation and risk of venous thromboembolism in glioma: A systematic review and meta-analysis.
Thromb Res. 2022 Sep 5, 2022;219:14-21. doi: 10.1016/j.thromres.2022.08.029. PMID: 36088710. Review, Meta-analysis˰




Mirzaei R, Yong VW.
Microglia-T cell conversations in brain cancer progression.
Trends Mol Med. 2022 Sep 5, 2022:S1471-4914(22)00211-8. doi: 10.1016/j.molmed.2022.08.006. PMID: 36075812. Review˰




Śledzińska P, Bebyn M, Furtak J, Koper A, Koper K.
Current and promising treatment strategies in glioma.
Rev Neurosci. 2022 Sep 6. doi: 10.1515/revneuro-2022-0060. PMID: 36062548. Review˰




Wang Z, Chen G.
Insights about circadian clock in glioma: From molecular pathways to therapeutic drugs.
CNS Neurosci Ther. 2022 Sep 6. doi: 10.1111/cns.13966. PMID: 36066207. Review.




Sethi B, Kumar V, Mahato K, Coulter DW, Mahato RI.
Recent advances in drug delivery and targeting to the brain.
J Control Release. 2022 Sep 7, 2022;350:668-687. doi: 10.1016/j.jconrel.2022.08.051. PMID: 36057395. Review˰




Pappo AS, Karol SE, Bertrand KC.
Top advances of the year: Pediatric oncology.
Cancer. 2022 Sep 8. doi: 10.1002/cncr.34425. PMID: 36074012. Review.




Khayamzadeh M, Niazi V, Hussen BM, Taheri M, Ghafouri-Fard S, Samadian M.
Emerging role of extracellular vesicles in the pathogenesis of glioblastoma.
Metab Brain Dis. 2022 Sep 9. doi: 10.1007/s11011-022-01074-6. PMID: 36083425. Review˰



*

Aquilanti E, Wen PY.
Current therapeutic options for glioblastoma and future perspectives.
Expert Opin Pharmacother. 2022 Sep 13. doi: 10.1080/14656566.2022.2125302. PMID: 36100970. Review˰




Naser R, Dilabazian H, Bahr H, Barakat A, El-Sibai M.
A guide through conventional and modern cancer treatment modalities: A specific focus on glioblastoma cancer therapy (Review).
Oncol Rep. 2022 Sep 13, 2022;48(5):190. doi: 10.3892/or.2022.8405. PMID: 36102321. Review˰




Pasqualetti F, Rizzo M, Franceschi S, Lessi F, Paiar F, Buffa FM.
New perspectives in liquid biopsy for glioma patients.
Curr Opin Oncol. 2022 Sep 13. doi: 10.1097/CCO.0000000000000902. PMID: 36093876. Review˰




Tran S, Bielle F.
WHO 2021 and beyond: new types, molecular markers and tools for brain tumor classification.
Curr Opin Oncol. 2022 Sep 13. doi: 10.1097/CCO.0000000000000903. PMID: 36093875. Review˰




Karam A, Mjaess G, Martinez Chanza N, Aoun F, Bou Kheir G, Younes H, Kazzi H, Albisinni S, Roumeguère T.
CAR-T cell therapy for solid tumors: are we still that far? A systematic review of literature.
Cancer Invest. 2022 Sep 14, 2022:1-35. doi: 10.1080/07357907.2022.2125004. PMID: 36102932. Review˰




Torres ID, Loureiro JA, Coelho MAN, Carmo Pereira M, Ramalho MJ.
Drug delivery in glioblastoma therapy: a review on nanoparticles targeting MGMT-mediated resistance.
Expert Opin Drug Deliv. 2022 Sep 14. doi: 10.1080/17425247.2022.2124967. PMID: 36103209. Review˰